Salidroside inhibits melanin synthesis and melanoma growth via mTOR and PI3K/Akt pathways
Frontiers in Oncology · 10.07.2025 · 15
DOI: 10.3389/fonc.2025.1583580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 10.07.2025. Verfasst von Qi Ouyang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control, Changsha Hospital for Maternal & Child Health Care Affil…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Melanomas are caused by the malignant transformation of melanocytes. Numerous studies have demonstrated that the tyrosol components of salidroside inhibit tyrosinase activity. The PI3K/Akt/mTOR signaling pathway plays a crucial role in biological pigment synthesis. However, how salidroside achieves its anti-melanoma effect in melanoma by regulating PI3K/Akt/mTOR remains poorly understood. This study aimed to explore the effect of salidroside on PI3K/Akt/mTOR in melanoma, which plays a role in regulating melanogenesis.
Methods
Network pharmacology was predicted that salidroside may exert an anti-melanoma effect through modulating melanin synthesis functions and signaling pathways. Zebrafish whole-embryo in situ hybridization, RT-qPCR, melanin synthesis and tumorigenesis assays, and were performed to investigate the therapeutic efficacy of salidroside in melanin synthesis. The mechanism of salidroside in anti-melanoma activity was examined by RT-qPCR, Western blot, immunofluorescence, in vivo imaging, immunohistochemistry.
Results
We confirmed salidroside may exert an anti-melanoma effect through modulating melanin synthesis-related gene expression and PI3K/Akt pathway by Network pharmacology. Furthermore, salidroside slowed melanin synthesis in zebrafish embryos and H 2 O 2 -induced B16F10 cells by inhibited oxidative stress. Moreover, we determined the effect of salidroside on anti-melanin synthesis via PI3K/Akt/mTOR pathway in vitro , and western blot results showed that salidroside increased the expression of Nrf2 in the nucleus, as well as inhibited the phosphorylation of mTOR and PI3K/Akt pathway. Finally, intratumoral administration showed salidroside suppressed melanoma growth.
Conclusion
Salidroside inhibits melanin synthesis and melanoma development most likely by its antioxidant properties and downregulating the PI3K/Akt/mTOR pathway. Our results may provide a novel therapeutic strategy for the treatment of melanoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control, Changsha Hospital for Maternal & Child Health Care Affiliated to Hunan Normal University, Hunan Normal University, Changsha, C…
- The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, China.
- Hunan Provincial Engineering Technology Research Center of Stem Cell Exosome, Hunan Landfar Biotechnology Co. Ltd., Changsha, China.
Zitieren
APA
Ouyang, Q., Tian, S., Zhou, H., Mao, Y., Li, X., Yan, F., Liu, A., Hu, X., You, C., & He, J. (2025). Salidroside inhibits melanin synthesis and melanoma growth via mTOR and PI3K/Akt pathways. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1583580
Vancouver
Ouyang Q, Tian S, Zhou H, Mao Y, Li X, Yan F, et al. Salidroside inhibits melanin synthesis and melanoma growth via mTOR and PI3K/Akt pathways. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1583580
BibTeX
@article{Ouyang2025,
author = {Ouyang, Qi and Tian, Shengye and Zhou, Hengyu and Mao, Ying and Li, Xiang and Yan, Feng and Liu, Ailong and Hu, Xiang and You, Changqiao and He, Jun},
title = {Salidroside inhibits melanin synthesis and melanoma growth via mTOR and PI3K/Akt pathways},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1583580}
}
EUVIMED